RBC Capital analyst Ashish Sabadra maintained a Buy rating on MSCI (MSCI – Research Report) yesterday and set a price target of $675.00. The ...

In a report released yesterday, Ashish Sabadra from RBC Capital maintained a Buy rating on Nasdaq (NDAQ – Research Report), with a price target ...

The firm acknowledges that Sunoco faces downside risks, which could stem from a negative shift in commodity market conditions or the economics of potential future projects and mergers and acquisitions ...

$180,000 of RBC CAPITAL MARKETS LLC (FORMERLY REGISTERED AS ROYAL BANK OF CANADA) lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on ...

RBC Capital Markets advised on a total of 34 deals ... Evercore was third with 19, Barclays came fourth with 18 and Goldman Sachs secured fifth spot with 16 deals. GlobalData’s league tables ...

RBC Capital Markets has promoted Adam Ragol-Levy to head of European and Asian product, multi-asset agency solutions. The appointment follows three years serving as global multi-asset product manager ...

But investors can still look forward to "solid" if more "moderate" returns in the year ahead, says RBC Capital Markets – and perhaps even better with the right stock investments. "The overall ...

"Prices have moved up nearly 16% since Thursday with no 'normal' reasons that could justify this price action," Tyler Broda, an RBC Capital Markets analyst, said in a February 1 research note.

On Thursday, RBC Capital Markets adjusted their stance on Neumora Therapeutics (NASDAQ:NMRA), downgrading the stock from an Outperform to a Sector Perform rating. This change comes in the wake of ...